Chemed (NYSE:CHE) Issues Quarterly Earnings Results

Key Points

• Chemed reported quarterly earnings of $3.75 per share, missing the expected $6.02 by $2.27.
• The company recently paid a quarterly dividend of $0.50 per share, representing an annualized dividend yield of 0.43%.
• Insiders sold a combined total of 4,500 shares of Chemed stock worth approximately $2.6 million in the last 90 days.

Chemed (NYSE:CHE - Get Free Report) released its quarterly earnings data on Tuesday. The company reported $4.27 EPS for the quarter, missing the consensus estimate of $6.02 by ($1.75), Briefing.com reports. Chemed had a net margin of 12.40% and a return on equity of 27.58%. The company had revenue of $618.80 million during the quarter, compared to analysts' expectations of $650.60 million. During the same period last year, the business earned $5.47 earnings per share. The company's revenue for the quarter was up 3.8% compared to the same quarter last year. Chemed updated its FY 2025 guidance to 22.000-22.300 EPS.

Chemed Stock Performance

Shares of NYSE CHE traded down $32.00 during trading on Wednesday, hitting $432.70. The company had a trading volume of 26,471 shares, compared to its average volume of 130,084. The company has a market cap of $6.33 billion, a P/E ratio of 20.98, a PEG ratio of 2.26 and a beta of 0.50. Chemed has a 52 week low of $410.00 and a 52 week high of $623.60. The business's 50-day moving average is $517.94 and its 200 day moving average is $555.29.

Chemed Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 17th. Shareholders of record on Thursday, May 29th were issued a $0.50 dividend. The ex-dividend date of this dividend was Thursday, May 29th. This represents a $2.00 annualized dividend and a dividend yield of 0.46%. Chemed's dividend payout ratio is currently 9.74%.

Insider Buying and Selling at Chemed

In other Chemed news, CEO Kevin J. Mcnamara sold 1,500 shares of the company's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $576.45, for a total value of $864,675.00. Following the transaction, the chief executive officer owned 101,197 shares of the company's stock, valued at approximately $58,335,010.65. This represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Spencer S. Lee sold 1,500 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $577.99, for a total transaction of $866,985.00. Following the sale, the executive vice president directly owned 14,627 shares in the company, valued at approximately $8,454,259.73. This trade represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 4,500 shares of company stock worth $2,598,450 in the last ninety days. 3.29% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Chemed

An institutional investor recently raised its position in Chemed stock. Geneos Wealth Management Inc. lifted its stake in Chemed Corporation (NYSE:CHE - Free Report) by 330.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 99 shares of the company's stock after buying an additional 76 shares during the period. Geneos Wealth Management Inc.'s holdings in Chemed were worth $61,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 95.85% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CHE. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $640.00 target price (down from $674.00) on shares of Chemed in a research report on Monday, June 30th. Jefferies Financial Group initiated coverage on Chemed in a research note on Friday, July 25th. They issued a "hold" rating and a $500.00 target price for the company. Wall Street Zen downgraded Chemed from a "buy" rating to a "hold" rating in a research note on Saturday, July 5th. Finally, Bank of America decreased their target price on Chemed from $708.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, June 30th.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.